Physics and Imaging in Radiation Oncology

本刊是 2017 年由欧洲放射治疗与肿瘤学会（ESTRO）创办的开放获取期刊，由 Elsevier 出版，发表放射治疗物理与医学影像方面的研究。

刊物聚焦放射治疗链条中的物理问题，从成像、计划设计、剂量计算到投照与验证，并把影像生物标志物与治疗反应的评估纳入视野。

2025 年影响因子为 3.2，五年影响因子为 3.4，在放射学、核医学与医学影像 217 种期刊中列第 64 位，在肿瘤学 333 种期刊中列第 161 位，均处于第二四分位。

Scope

• Physics and Imaging in Radiation Oncology publishes work on the physical and imaging basis of radiotherapy.本刊发表放射治疗物理与影像基础方面的研究。
• Treatment planning studies compare dose algorithms, optimisation strategies and plan robustness.治疗计划研究比较剂量算法、优化策略与计划的稳健性。
• Image guidance covers cone-beam computed tomography, magnetic resonance imaging and surface tracking in the treatment room.影像引导涵盖锥形束计算机断层成像、磁共振成像与治疗室内的表面追踪。
• Adaptive radiotherapy, including offline and online replanning, is a growing part of the journal's content.自适应放射治疗，包括离线与在线重新计划，在刊物内容中占比日增。
• Particle therapy physics, from proton and carbon beam modelling to range verification, is represented.粒子治疗物理从质子与碳束建模到射程验证均有涉及。
• Dosimetry papers address detectors, calibration and the verification of delivered dose in phantoms and patients.剂量学研究涉及探测器、刻度以及在体模和患者中验证实际投照剂量。
• Automation and artificial intelligence for segmentation, planning and quality assurance are within scope.用于勾画、计划与质量保证的自动化与人工智能方法在收稿范围之内。
• Quantitative imaging and radiomics are examined where they inform radiotherapy decisions rather than stand alone.定量影像与影像组学在服务于放射治疗决策而非孤立展示时受到考察。
• Clinical implementation studies report how a new technique performs in routine practice and at what cost.临床实施研究报告新技术在常规实践中的表现及其代价。
• Quality assurance, audit and multicentre trial physics are treated as research topics in their own right.质量保证、审计与多中心试验物理被当作独立的研究课题。
• Work on treatment machines, brachytherapy sources and immobilisation devices is accepted when the physics question is clear.治疗机、近距离治疗源与固定装置的物理研究，只要问题明确即可接受。
• Educational and review articles explain emerging methods to a clinical physics readership.教学与综述文章向临床物理读者解释新兴方法。
• Short technical notes describe a device or a workflow that others can adopt without a full trial.技术短文介绍他处可直接采用的装置或流程，无须完整试验。
• Letters to the editor and author replies allow rapid exchange on published results.读者来信与作者答复使已发表结果得到快速交流。
• Small-animal irradiators and preclinical beam lines are studied for translational work that precedes clinical trials.小动物照射装置与临床前束流用于临床试验之前的转化研究。
• In vivo dosimetry and electronic portal imaging provide evidence that the planned dose reached the patient.在体剂量测量与电子射野成像为计划剂量抵达患者提供证据。
• Knowledge-based planning and deep learning dose prediction are evaluated against conventional optimisation.知识库计划与深度学习剂量预测被拿来和常规优化方法比较。
• Magnetic resonance guided radiotherapy raises questions of field homogeneity and dose calculation in a magnetic field.磁共振引导放疗提出磁场均匀性与磁场中剂量计算的问题。
• Multicentre studies on contouring variability and plan quality aim at harmonising practice across institutions.关于勾画差异与计划质量的多中心研究力图使各机构做法趋于一致。
• Open data and shared code are encouraged so that physics results can be reproduced by other groups.刊物鼓励开放数据与共享代码，使物理结果能被其他课题组复现。
• Patient-specific quality assurance studies compare measurement-based checks with independent dose recalculation.患者个体化质量保证研究比较基于测量的核查与独立剂量重算。
• Imaging for target definition in moving tumours links four-dimensional imaging to margin design.用于运动肿瘤靶区勾画的影像把四维成像与边界设计联系起来。
• Brachytherapy planning papers address source tracking and the dosimetry of small volumes.近距离治疗计划研究处理源位置追踪与小体积剂量学。

History

• The journal was launched in January 2017 by the European Society for Radiotherapy and Oncology.刊物由欧洲放射治疗与肿瘤学会于 2017 年 1 月创刊。^[1]
• It was created to give radiotherapy physics and imaging a dedicated open access venue within the ESTRO family.创办它的目的是在学会的期刊系列中为放射治疗物理与影像提供一个专门的开放获取平台。
• The first volume appeared in 2017, and the journal has since published about four volumes a year.首卷于 2017 年问世，此后每年大约出版四卷。
• Volume 37 is scheduled for 2026, a pace that reflects steady growth in submissions.2026 年将出版第 37 卷，这一节奏反映出投稿量的稳定增长。
• All articles are open access under a Creative Commons Attribution-NonCommercial-NoDerivatives licence.所有文章以知识共享署名非商业禁止演绎许可开放获取。
• The journal is part of the ESTRO family alongside Radiotherapy and Oncology, Clinical and Translational Radiation Oncology and Technical Innovations and Patient Support in Radiation Oncology.刊物与学会旗下的临床放疗期刊、转化放疗期刊以及技术创新与患者支持期刊同属一个系列。
• Manuscripts that fit a sister journal better can be transferred within the family with the authors' consent.更适合姊妹刊的稿件经作者同意可在系列内转投。
• The journal has published joint special issues with its sister titles on topics that span physics and clinical practice.刊物与姊妹刊就横跨物理与临床实践的题目出版过联合专刊。
• It received its first impact factor of 3.7 in June 2023, six years after launch.创刊六年后的 2023 年 6 月，刊物获得首个影响因子 3.7。
• Impact factors since then were 3.4 in 2023, 3.3 in 2024 and 3.2 in 2025.此后影响因子依次为 2023 年的 3.4、2024 年的 3.3 与 2025 年的 3.2。^[2]
• The journal is indexed in the Emerging Sources Citation Index and in Scopus.刊物被新兴来源引文索引与 Scopus 收录。
• In 2023 the editors reported about 240 submissions and 117 published papers for the year.2023 年编辑部报告全年约收到 240 篇投稿，发表 117 篇论文。
• The share of submissions from Asia rose from about one tenth to a quarter within a few years.来自亚洲的投稿比例在数年内从约十分之一上升到四分之一。
• The editorial board was expanded in 2024 with associate editors for computer science and for adaptive and four-dimensional physics.2024 年编委会增设负责计算机科学以及自适应与四维物理的副编辑。
• A mentorship scheme pairs early-career physicists with experienced reviewers and editors.导师计划把青年物理学者与有经验的审稿人和编辑配对。
• The article processing charge is 2,080 United States dollars, and the journal reports a single anonymous review model.文章处理费为 2080 美元，刊物采用单匿名评审模式。

Editors

• Ludvig P. Muren of the Danish Centre for Particle Therapy at Aarhus University Hospital is editor-in-chief.奥胡斯大学医院丹麦粒子治疗中心的 Ludvig P. Muren 担任主编。
• Muren's own research concerns proton therapy planning and the modelling of treatment uncertainty.Muren 本人的研究涉及质子治疗计划与治疗不确定性的建模。
• Barbara Knäusl of the Medical University of Vienna is an associate editor and works on particle therapy dosimetry.维也纳医科大学的 Barbara Knäusl 是副编辑，研究粒子治疗剂量学。
• Timothy D. Solberg of the University of Washington is an associate editor with a background in clinical physics.华盛顿大学的 Timothy D. Solberg 是副编辑，具有临床物理背景。
• Daniela Thorwarth of the University of Tübingen is an associate editor working on functional and molecular imaging.蒂宾根大学的 Daniela Thorwarth 是副编辑，研究功能与分子影像。
• Further associate editors joined in 2024 to cover machine learning and adaptive treatment delivery.2024 年又有副编辑加入，负责机器学习与自适应投照。
• The board draws on clinical physicists, radiation oncologists and imaging scientists from across Europe and beyond.编委会由来自欧洲及其他地区的临床物理师、放射肿瘤医师与影像科学家组成。
• Handling editors assign each manuscript to at least two independent reviewers.负责编辑为每篇稿件指派至少两位独立审稿人。
• Review is single anonymous, so reviewers know the authors while authors do not know the reviewers.评审采用单匿名方式，审稿人知道作者身份，作者不知审稿人是谁。
• The journal aims to return a first decision within a few weeks of submission.刊物力求在投稿后数周内给出初审决定。
• Editors encourage authors of rejected papers to transfer to a sister journal when the work remains sound.对于工作本身可靠的被拒稿件，编辑鼓励作者转投姊妹刊。
• Guest editors lead special issues, often in cooperation with the ESTRO physics committee.专刊由客座编辑主持，常与学会的物理委员会合作。
• The editorial office in Vienna coordinates submission, review and production with Elsevier.编辑事务由主编与 Elsevier 的出版团队共同处理。
• Authors may appeal a decision in writing, and appeals are handled by an editor who was not involved.作者可以书面申诉，申诉由未参与原决定的编辑处理。